Table 4.

Complications before and after switch.

	Fast Metabolizers n = 58	Slow Metabolizers n = 22	p-Value
CMV infection
before switch to LCPT	8 (13.8%)	2 (9.1%)	0.719
after switch to LCPT (3 y-follow up)	3 (5.2%)	2 (9.1%)	0.612
BKV infection
before switch to LCPT	3 (5.2%)	3 (13.6%)	0.338
after switch to LCPT (3 y-follow up)	1 (1.7%)	0	1
BKV nephropathy
before switch to LCPT	1 (1.7%)	2 (9.1%)	0.182
after switch to LCPT (3 y-follow up)	0	0	-
CNIT
before switch to LCPT	3 (5.2%)	2 (9.1%)	0.612
after switch to LCPT (3 y-follow up)	1 (1.7%)	0	1
acute rejection
before switch to LCPT	12 (20.7%)	9 (40.9%)	0.089
after switch to LCPT (3 y-follow up)	8 (13.8%)	2 (9.1%)	0.719
death within 3 years after switch	2 (3.4%)	0	1
diabetes mellitus
before switch to LCPT	1 (1.7%)	1 (4.5%)	0.477
after switch to LCPT (3 y-follow up)	0	0	-

CMV, cytomegalovirus; BKV, BK-virus; CNIT, calcineurin-inhibitor nephrotoxicity; LCPT, LCP-tacrolimus. p-values are from the Fisher’s exact test.